<DOC>
	<DOCNO>NCT00110058</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine , radiation therapy donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) interferon alfa transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine together radiation therapy work treat patient undergo donor stem cell transplant chronic phase accelerate phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Fludarabine Radiation Therapy Treating Patients Who Are Undergoing Donor Stem Cell Transplant Chronic Phase Accelerated Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine disease-free survival rate patient chronic accelerated phase chronic myelogenous leukemia fail inadequately responded prior imatinib mesylate treat nonmyeloablative conditioning comprise fludarabine low-dose total-body irradiation follow allogeneic peripheral blood stem cell transplantation . Secondary - Determine complete cytogenetic molecular response rate patient treated regimen . - Determine overall survival patient treat regimen . - Determine non-relapse mortality patient treat regimen . - Determine incidence serious infection , graft-versus-host disease , myelosuppression patient treat regimen . OUTLINE : This multicenter study . - Conditioning treatment : Patients receive fludarabine IV day -4 -2 . Patients undergo low-dose total-body irradiation ( TBI ) day 0 . - Allogeneic peripheral blood stem cell transplantation : After TBI , patient undergo allogeneic peripheral blood stem cell transplantation day 0 . - Immunosuppression : Patients receive oral cyclosporine twice daily day -3 56 followed taper day 180 absence graft-versus-host disease ( GVHD ) . Patients also receive oral mycophenolate mofetil twice daily day 0-27 . - Post-transplant treatment : Patients experience disease persistence progression AND low donor chimerism discontinue immunosuppression . Patients disease persistence progression discontinue immunosuppression receive oral imatinib mesylate daily . Patients disease improvement day 28 imatinib mesylate treatment AND evidence disease day 84 imatinib mesylate treatment continue imatinib mesylate absence disease progression unacceptable toxicity . Patients fail improve day 28 imatinib mesylate treatment OR residual disease day 84 imatinib mesylate treatment receive donor lymphocyte IV 15-30 minute every 1-4 month 4 infusion . Patients ineligible receive donor lymphocyte ( e.g. , patient evidence GVHD ) receive interferon alfa subcutaneously 3 time week 12 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 , 9 , 12 , 18 , 24 month , annually 5 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Philadelphia chromosomepositive ( Ph+ ) chronic myelogenous leukemia , meet 1 follow criterion : Chronic phase Ph+ cytogenetics fluorescent situ hybridization ( FISH ) assay Accelerated phase , meet follow criterion : More 10 % &lt; 30 % myeloblast promyelocytes marrow peripheral blood Any additional clonal cytogenetic abnormality Increasing splenomegaly Extramedullary tumor WBC , platelet count , hematocrit perturbation control therapy hydroxyurea , interferon , imatinib mesylate Persistent unexplained fever bone pain Less 5 % blast marrow time transplantation Not eligible OR refuse conventional myeloablative allogeneic stem cell transplantation Failed OR suboptimal response prior imatinib mesylate , define 1 following : Absence complete hematologic response &gt; 3 month treatment imatinib mesylate Absence cytogenetic response , define 1 following : Absence cytogenetic response ( &lt; 95 % Ph+ BCR/ABL+ cell cytogenetic FISH analysis , respectively ) 6 month treatment imatinib mesylate Absence major cytogenetic response ( &lt; 35 % Ph+ BCR/ABL+ cell cytogenetic FISH analysis , respectively ) 1 year treatment imatinib mesylate Absence complete cytogenetic response ( Ph+ cell cytogenetic analysis OR BCR/ABL+ cell within normal limit FISH analysis ) 18 month treatment imatinib mesylate Hematologic evidence disease progression Cytogenetic evidence disease progression Increase Ph+ cell BCR/ABL+ cell &gt; 20 % least 1 month sequential test Molecular evidence disease progression More 10fold increase BCR/ABL mRNA level quantitative polymerase chain reaction ( QPCR ) least 1 month 2 sequential test Experienced adverse event treatment imatinib mesylate preclude administration drug No CNS disease refractory intrathecal chemotherapy HLA identical relate donor available Phenotypically match HLAA , B , C , DRQ1 , DBQ1 No presence circulate leukemic blast standard pathology PATIENT CHARACTERISTICS : Age Any age Performance status Karnofsky 70100 % OR Lansky 70100 % Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic No fulminant liver failure No cirrhosis liver evidence portal hypertension bridge fibrosis No alcoholic hepatitis No esophageal varices No history bleed esophageal varix No hepatic encephalopathy No uncorrectable hepatic synthetic dysfunction evidence prolongation PT No ascites relate portal hypertension No bacterial fungal liver abscess No biliary obstruction No chronic viral hepatitis AND bilirubin &gt; 3 mg/dL No symptomatic biliary disease Renal Renal failure allow Cardiovascular No symptomatic coronary artery disease Ejection fraction ≥ 35 % No cardiac failure require therapy No poorly control hypertension ( blood pressure ≥ 150/90 mm Hg ) standard medication Pulmonary DLCO ≥ 30 % Total lung capacity ≥ 30 % FEV_1 ≥ 30 % No requirement continuous supplementary oxygen No fungal pneumonia radiological progression treatment amphotericin moldactive azoles &gt; 1 month Other Not pregnant nursing Fertile patient must use effective barrier contraception 12 month completion study treatment HIV negative No disease severely limit life expectancy No active malignancy except localized nonmelanoma skin cancer No nonhematologic malignancy within past 5 year currently complete remission &gt; 20 % risk disease recurrence except nonmelanoma skin cancer No systemic uncontrolled infection No active bacterial fungal infection unresponsive medical therapy PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 48 hour since prior imatinib mesylate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>